Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia

被引：0
|
作者：
Seymour, John [1 ,2 ,3 ]
机构：
[1] Peter MacCallum Canc Ctr, Clin Res, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 08期
关键词：
NAVITOCLAX; RITUXIMAB;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：440 / 443
页数：4
相关论文
共 50 条
  • [41] Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment
    Li, Pengfei
    Luo, Zhiming
    Deng, Jianchuan
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [42] BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML
    Brandwein, Joseph M.
    Basonbul, Asmaa
    BLOOD, 2019, 134
  • [43] Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects
    Cheung, Tommy T.
    Salem, Ahmed Hamed
    Menon, Rajeev M.
    Munasinghe, Wijith P.
    Bueno, Orlando F.
    Agarwal, Suresh K.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (04): : 435 - 440
  • [44] Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment
    Ahmed Hamed Salem
    Nimita Dave
    Thomas Marbury
    Beibei Hu
    Dale Miles
    Suresh K. Agarwal
    Orlando F. Bueno
    Rajeev M. Menon
    Clinical Pharmacokinetics, 2019, 58 : 1091 - 1100
  • [45] Incidence of 5' bcl-2 rearrangement in patients with B cell chronic lymphocytic leukemia from India
    Parikh, PM
    Desai, S
    Naresh, KN
    Shakuntaka, B
    Laxminarayan, K
    Nair, CN
    Ladanyi, M
    Soman, CS
    Advani, SH
    Chaganti, RSK
    LEUKEMIA RESEARCH, 1996, 20 (09) : 791 - 793
  • [46] Venetoclax for the treatment of chronic lymphocytic leukemia
    Gentile, Massimo
    Petrungaro, Annamaria
    Uccello, Giuseppina
    Vigna, Ernesto
    Recchia, Anna Grazia
    Caruso, Nadia
    Bossio, Sabrina
    De Stefano, Laura
    Palummo, Angela
    Storino, Francesca
    Martino, Massimo
    Morabito, Fortunato
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1307 - 1316
  • [47] Venetoclax in the treatment of chronic lymphocytic leukemia
    Korycka-Wolowiec, Anna
    Wolowiec, Dariusz
    Kubiak-Mlonka, Aleksandra
    Robak, Tadeusz
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (05) : 353 - 366
  • [48] Venetoclax and obinutuzumab in chronic lymphocytic leukemia
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fink, Anna-Maria
    Dixon, Mark
    Bahlo, Jasmin
    Warburton, Simon
    Kipps, Thomas J.
    Weinkove, Robert
    Robinson, Sue
    Seiler, Till
    Opat, Stephen
    Owen, Carolyn
    Lopez, Javier
    Humphrey, Kathryn
    Humerickhouse, Rod
    Tausch, Eugen
    Frenzel, Lukas
    Eichhorst, Barbara
    Wendtner, Clemens-M.
    Stilgenbauer, Stephan
    Langerak, Anton W.
    van Dongen, Jacque J. M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Goede, Valentin
    Mobasher, Mehrdad
    Hallek, Michael
    BLOOD, 2017, 129 (19) : 2702 - 2705
  • [49] Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
    Herbert Eradat
    Current Hematologic Malignancy Reports, 2019, 14 : 469 - 476
  • [50] Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1500): : 101 - 102
12345